Literature DB >> 2782734

Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.

B J Lipworth1, A D Struthers, D G McDevitt.   

Abstract

High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma, and are associated with dose-dependent systemic beta-adrenoceptor responses. The purpose of the present study was to investigate whether tachyphylaxis occurs during prolonged treatment with high dose inhaled salbutamol. Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms). Treatment had no significant effect on baseline values. There were dose-dependent increases in FEV1 and FEF25-75 (p less than 0.001), and pretreatment with HDS did not displace the DRC to the right. DRC for HR (p less than 0.001), K (p less than 0.001), and Glu (p less than 0.005) were attenuated after treatment with HDS compared with PI. There were also differences between HDS and LDS for HR (p less than 0.001) and Glu (p less than 0.05) responses. Frequency and severity of subjective adverse effects were also reduced after HDS: tremor (p less than 0.001), palpitations (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2782734     DOI: 10.1164/ajrccm/140.3.586

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  38 in total

1.  Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 3.  Antagonism of long-acting beta2-adrenoceptor agonism.

Authors:  Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

4.  Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.

Authors:  D M Newnham; A Grove; D G McDevitt; B J Lipworth
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

6.  Treatment of Difficult Asthma: What do you do when asthma doesn't respond to therapy?

Authors:  D M Bowie
Journal:  Can Fam Physician       Date:  1991-04       Impact factor: 3.275

7.  Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol.

Authors:  B J Lipworth; R A Clark; D P Dhillon; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.

Authors:  H Booth; K Fishwick; R Harkawat; G Devereux; D J Hendrick; E H Walters
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

Review 9.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 10.  Beta 2 adrenergic receptors in asthma: a current perspective.

Authors:  T R Bai
Journal:  Lung       Date:  1992       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.